Virax Biolabs Group Limited · NASDAQ:VRAX
Virax Biolabs — IPO Roadshow (July 2022)
23 slides from Virax Biolabs's IPO roadshow presentation, Jul 1, 2022
Slide 1: Investor Presentation – June 2022
Investor Presentation – June 2022 Past performance is not indicative of future results. Investments may be speculative, illiquid, and there is a risk of princi pal loss. There is no guarantee that any specific outcome will be achieved. Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer
Slide 2: Forward-looking statements and Free Writing Prospectus
2 This document contains forward - looking statements. In addition, from time to time, we or our representatives may make forward - lo oking statements orally or in writing. We base these forward - looking statements on our expectations and projections about future events, which we derive from the i
Slide 3: Risk Factors
3 We have limited operating history, have incurred operating losses for the six months ended September 30, 2021 and the years ended March 31, 2021 and 2020 and expect to incur significant losses for the foreseeable future. We may not generate sufficient revenue or become profitable or, if we achieve
Slide 4: Risk Factors (continued)
4 We face risks related to natural disasters, health epidemics and other outbreaks, specifically the coronavirus, which could significantly disrupt our operations. If we are not able to adequately protect our proprietary intellectual property and information, and protect against third party claims t
Slide 5: Risk Factors: subsidiaries, dividends and regional risks
5 We may rely on dividends and other distributions on equity paid by our subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our subsidiaries to make payments to us could have a material adverse effect on our ability to conduct our business. Dev
Slide 6: Risk Factors: dividends, foreign private issuer
6 We do not intend to pay cash dividends on our Ordinary Shares in the foreseeable future. We are an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements. We qualify as a foreign private issuer and, as a result, we will not
Slide 7: Offering Summary
7 Issuer Virax Biolabs Group Limited Exchange & Ticker Nasdaq Capital Market Reserved Symbol : VRAX Shares Outstanding Prior to Completion of the IPO 10 , 024 , 098 Ordinary Shares, and no shares of Preferred Stock Class A Ordinary Shares Offered 1 , 350 , 000 Ordinary Shares Shares Outstanding Imme
Slide 8: Overview
Overview 8 Virax Biolabs is an innovative biotechnology company focused on the detection and diagnosis of viral diseases. Virax Biolabs believes it is developing a game - changing immunology platform based around our proprietary T - Cell testing technology, which is particularly effective in the dia
Slide 9: Business Segments
9 PREVENTION – ViraxCare is focused on offering preventative measures against viral threats through its Internet of Healthcare Things & Medtech solutions. PROFILING – The Virax Immune platform provides T - Cell diagnostics focused on longer term immunological profiling DIAGNOSIS – ViraxClear provide
Slide 10: Market Opportunity
10 Virax’s target markets in aggregate are anticipated to double in value by 2026. Virax’s primary focus is on the In Vitro Diagnostics (IVD) market, which is expected to double in size over the next 5 years. 1. Source: Globe News Wire, https://www.globenewswire.com/news - release/2019/07/03/1877759
Slide 11: IVD Market Overview
11 IVD Market Saturation In Vitro Diagnostics Market Overview Past performance is not indicative of future results. Investments may be speculative, illiquid, and there is a risk of princi pal loss. There is no guarantee that any specific outcome will be achieved. 3. Source: Investment Bank, https://
Slide 12: ViraxClear – Products
12 TEST PRODUCT APPROVAL REGIONAL APPROVALS SALES/REVENUE ViraxClear Covid - 19 Rapid Antibody IgC /IgM Test — Approved in Europe, South America, Southeast Asia — Revenue generating since 2020 ViraxClear Covid - 19 Antigen Test — Approved in Europe, South America, Southeast Asia — Revenue generating
Slide 13: ViraxCare – Products
13 PRODUCT DEVELOPMENT PRODUCT APPROVALS SALES/REVENUE Employee Protection Equipment Plus — PPE tech approval for Europe and North America — Development began 2017 — Revenue generating since 2020 ViraxCare AI - powered Sanitizing Bot — European Approval — Sales to commence Q3 2022 — Intention to bui
Slide 14: T-Cells and viral immunity
14 T - Cells coordinate the immune system against viral attacks, unlike antibodies. T - Cell detection can give an indication of inherent protection to a range of diseases for those yet to be infected. T - Cells have been shown to provide a level of protection against Covid - 19 and its variants tha
Slide 15: Virax Immune T-Cell Testing & Immunity Mobile App
15 In Development Virax Immune T - Cell Testing & Immunity Mobile App Past performance is not indicative of future results. Investments may be speculative, illiquid, and there is a risk of princi pal loss. There is no guarantee that any specific outcome will be achieved. PRODUCT DEVELOPMENT STAGE Vi
Slide 16: Virax's T-Cell Testing Process
16 Future Developments Biosensor technology Square wave voltammetry electrical measurement techniques Shift towards POC and home - based testing comparable to lab - based ELISA tests.* * Neither the Company nor BSL makes any express or implied representation or warranty as to the certainty or assura
Slide 17: Virax Immune – Commercialization
17 Virax Immune – Commercialization In Development Past performance is not indicative of future results. Investments may be speculative, illiquid, and there is a risk of princi pal loss. There is no guarantee that any specific outcome will be achieved. Virax believes that traditional forms of viral
Slide 18: Competitors and points of difference
18 19. As of 24/05/2022, source: Google Finance COMPETITOR DETAILS VIRAX IMMUNE POINT OF DIFFERENCE Oxford Immunotec is a diagnostics company that currently offers a T - Cell Test for COVID, Cytomegalovirus and Tuberculosis. The Company was recently acquired by Perkin Elmer in January 2021 for $591
Slide 19: Where Could Virax Be In The Future?
COMPETITOR STOCK TICKER NASDAQ: ADPT NYSE: QGEN CURRENT MARKET CAP $1.12 billion $10.44 billion COMPANY DETAILS • Currently own and operate 33 active patents • Completed IPO in 2019. • Not profitable but revenue generating to this day. • Raised $465.69mm in order to get to IPO. • Has had to raise si
Slide 20: Management Team
20 James Foster Chief Executive Officer James has been an Asia - focused investment, product development and distribution expert in the medical device and pharmaceutical sector for over 10 years. Cameron Shaw Chief Operations Officer Cameron has a depth of experience in Business Development, Strateg
Slide 21: Investment Highlights
21 Our Platform is a Disruptive, Innovative Growth Engine Virax Biolabs is positioned to be a growth - oriented biotechnology company with the launch of Virax Immune. We believe our product suite is disruptive, innovative and will gain market share rapidly. Intellectual Property Protection Our Intel
Slide 22: Office Locations & Contact
22 Office Locations & Contact Past performance is not indicative of future results. Investments may be speculative, illiquid, and there is a risk of princi pal loss. There is no guarantee that any specific outcome will be achieved. Online www.viraxbiolabs.com info@viraxbiolabs.com London Headquarter
Slide 23: Thank You
Thank You www.viraxbiolabs.com